- Previous Close
37.05 - Open
36.90 - Bid 36.10 x --
- Ask 36.20 x --
- Day's Range
36.05 - 36.90 - 52 Week Range
36.05 - 76.50 - Volume
740,314 - Avg. Volume
573,614 - Market Cap (intraday)
27.806B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-3.35 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications. It also provides healthcare consulting, staffing, and MDS solutions. The company was founded in 1988 and is based in Tampa, Florida.
www.polaris-group.comRecent News: 6550.TW
View MorePerformance Overview: 6550.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6550.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6550.TW
View MoreValuation Measures
Market Cap
27.81B
Enterprise Value
26.56B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
252.01
Price/Book (mrq)
4.15
Enterprise Value/Revenue
248.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.07%
Return on Equity (ttm)
-35.32%
Revenue (ttm)
107M
Net Income Avi to Common (ttm)
-2.5B
Diluted EPS (ttm)
-3.35
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95B
Total Debt/Equity (mrq)
27.79%
Levered Free Cash Flow (ttm)
-2.85B